VIVUS (VVUS) Peers Tick Higher Amid Positive Qsymia Data (ARNA) (OREX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Medifast launches Trilivy, replacing its Optavia brand
VIVUS, Inc. (VVUS) Qsymia Prescriptions Show Gains During Slow Holiday Week (ARNA) (OREX)
February 4, 2013 10:45 AM ESTVIVUS, Inc. (Nasdaq: VVUS) is lower on the session amid new data for prescriptions of its weight-loss pill, Qsymia.
According to Bloomberg Industries, Qsymia prescriptions rose 24 percent to 2,859 last week. Data comes from Symphony Health Solutions.
Bloomberg also noted that... More
VIVUS (VVUS) Reports Publication of Signifianct Data from Recent Qsymia Study
February 1, 2013 7:15 AM ESTVIVUS, Inc. (Nasdaq: VVUS) announces the publication of a study concluding that weight loss resulting from treatment with Qsymia (phentermine and topiramate extended-release) capsules CIV led to significant improvements in cholesterol, blood pressure and triglycerides in obese and overweight patients experiencing one or more of these... More
